Angiotensin Converting Enzyme 2 News and Research

RSS

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

In a recent and timely paper, currently available on the bioRxiv preprint server, researchers from Israel and France demonstrated how in vitro evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) follows contagious mutation spread – but can also generate an efficient infection inhibitor.

10 Jan 2021

Researchers pinpoint spike protein regions as targets for passive and active COVID-19 vaccines

Researchers at Stanford University School of Medicine have identified regions of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have relatively few mutations and might therefore serve as important targets for prophylactic agents against coronavirus disease 2019 (COVID-19).

10 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Potential treatment approach to new COVID-19 variant

Researchers in the United States have demonstrated a potential new approach to treating infection with the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

7 Jan 2021

Which strain should SARS-CoV-2 vaccine candidates target?

A researcher at Clemson University, USA, has recently explored how governments might effectively combat the pandemic through strategic vaccination as new variants and strains of the virus emerge. The study suggests that vaccine candidates should target the fast-spreading variant, even when the initial prevalence is much lower.

7 Jan 2021

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

SARS-CoV-2 infected alveolar type-II lung cells show senescence

Using monoclonal antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and senescent markers, researchers provide evidence that virus-infected lung cells acquire characteristics of cellular senescence, which also leads to expression of proinflammatory cytokines.

5 Jan 2021

SARS-CoV-2 spike-antibody binding strength and hydrogen bond numbers are temperature dependent, study finds

A new preprint on the bioRxiv* server describes the interactions between the binding spike protein of the SARS-CoV-2 virus with the antibodies. Earlier studies have addressed the similarity in the 3D structures of the spike protein in the two SARS viruses as seen on cryo-EM.

24 Dec 2020

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

In a new study, released on the bioRxiv* preprint server, a team of researchers explores the antiviral potential of red blood cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19.

24 Dec 2020

Animal study suggests palmitoylation inhibitor reduces virulence of SARS-CoV-2

A new study preprint on the bioRxiv* server demonstrates the ability of a fatty acid synthase inhibitor to improve the survival of mice infected with murine hepatitis virus. In so doing, it adds to the sum of knowledge about the relationship of SARS-CoV-2 with cholesterol metabolism in the host cell.

24 Dec 2020

A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro

Researchers found that cetylpyridinium chloride, found in most mouthwashes, lowers infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, likely by inhibiting viral fusion with target cells. With more tests to prove validity, mouthwashes could be a simple, cheap way of curbing transmission.

24 Dec 2020

COVID-19 severity could be linked to genetic variance

A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.

23 Dec 2020

Scientists isolate anti-COVID-19 nanobodies produced by a llama

National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or "nanobodies," against SARS-CoV-2 that were produced by a llama named Cormac.

22 Dec 2020

Prior use of renin-angiotensin system inhibitors linked to reduced risk of death in older COVID-19 patients with hypertension

A new study, appearing as a preprint on the medRxiv* server, demonstrates the protective effect of drugs in older COVID-19 patients with hypertension.

21 Dec 2020

SARS-CoV-2 spike protein remains remarkably conserved among 37 variants from Hong Kong

As the coronavirus disease 2019 (COVID-19) pandemic continues to intensify in many parts of the world, vaccine development is proceeding apace.

21 Dec 2020

Angiotensin Converting Enzyme 2 News and Research

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

Researchers pinpoint spike protein regions as targets for passive and active COVID-19 vaccines

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Potential role of chitinase 3-like-1 in severity of COVID-19

Potential treatment approach to new COVID-19 variant

Which strain should SARS-CoV-2 vaccine candidates target?

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Are SARS-CoV-2 antibodies associated with disease enhancement?

SARS-CoV-2 infected alveolar type-II lung cells show senescence

SARS-CoV-2 spike-antibody binding strength and hydrogen bond numbers are temperature dependent, study finds

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

Animal study suggests palmitoylation inhibitor reduces virulence of SARS-CoV-2

A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro

COVID-19 severity could be linked to genetic variance

Scientists isolate anti-COVID-19 nanobodies produced by a llama

Prior use of renin-angiotensin system inhibitors linked to reduced risk of death in older COVID-19 patients with hypertension

SARS-CoV-2 spike protein remains remarkably conserved among 37 variants from Hong Kong

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News